USANA Health Sciences, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2012; comparative periods ended July 2, 2011. The request metadata identifies 2011 Q2, but the filing itself is for 2012 Q2. Financial amounts below are in U.S. dollars; millions unless noted.
Business context
USANA develops and manufactures nutritional and personal-care products sold internationally through independent associates using a direct-selling model. At June 30, 2012, it reported approximately 235,000 active associates and 66,000 active preferred customers. Associates generated 90% of product sales in the first half. The company operates in one reportable business segment, with sales across North America/Europe and Asia Pacific.
Financial results
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Net sales | $160.9 | $148.9 | $315.0 | $292.5 |
| Gross profit | $132.8 | $122.7 | $259.7 | $240.6 |
| Gross margin | 82.6% | 82.4% | 82.4% | 82.3% |
| Operating earnings | $25.2 | $21.2 | $46.0 | $38.4 |
| Net earnings | $16.7 | $13.9 | $30.5 | $25.2 |
| Diluted EPS | $1.11 | $0.88 | $2.01 | $1.58 |
| Operating cash flow | Not stated | Not stated | $43.9 | $31.4 |
Q2 sales increased 8.0%, net earnings 20.9%, and diluted EPS 26.1%. First-half sales increased 7.7%, net earnings 21.0%, and diluted EPS 27.2%. Q2 operating margin was approximately 15.6%, versus 14.2% a year earlier. The filing attributes earnings growth primarily to higher sales, improved gross margin, lower associate incentives as a share of sales, and a lower effective tax rate.
- Q2 regional sales: North America/Europe $62.5 million (+3.6%); Southeast Asia/Pacific $34.3 million (+25.9%); Greater China $56.8 million (+5.8%); North Asia $7.4 million (-4.6%). Asia Pacific represented 61.2% of Q2 sales.
- At June 30, cash and cash equivalents were $65.5 million, current assets $123.5 million, and current liabilities $66.7 million; net working capital was $56.8 million. Cash increased from $50.4 million at year-end 2011.
- The $60 million Bank of America credit facility, expiring April 2016, had no balance outstanding; the company reported compliance with its covenants. A separate $0.6 million short-term foreign-currency borrowing was outstanding and due July 31, 2012. No material change in market-risk disclosures was reported.
- First-half capital expenditures were $3.4 million. The company repurchased and retired 0.7 million shares for $26.6 million, averaging $39.26 per share; $23.4 million remained authorized at June 30.
Changes, outlook, and risks
- Sales growth was supported by increased associate activity, price increases in certain markets, the new Lifetime Matching Bonus and a related short-term promotion, and the launch of Thailand, France, and Belgium. The promotion contributed an estimated $4.6 million to Q2 sales; price increases contributed an estimated $4.7 million. Currency movements reduced Q2 sales by approximately $2.7 million.
- Management attributed Q2 gross-margin improvement partly to price increases and lower freight costs, partly offset by higher raw-material costs. Associate incentives declined to 44.1% of sales from 45.5% in Q2 2011. SG&A rose to 22.9% of sales from 22.7%, including new-market, equity-compensation, and wage costs.
- The Q2 effective tax rate was 32.8%, compared with 34.5%; the first-half rate was 33.6%, compared with 34.5%. The decrease primarily reflected a one-time favorable adjustment to deferred tax assets and liabilities following restructuring of Hong Kong and Singapore operations.
- Active associates increased 5.9% year over year, while active preferred customers declined 2.9%. Management cited North American stabilization and growth, expansion in Greater China, and international expansion as priorities. New-market sales growth in Thailand, France, and Belgium was expected to be slower than initially anticipated; those markets contributed $1.2 million in Q2.
- No quantified earnings or revenue guidance was provided. Management said cash, operating cash flow, and available credit were expected to fund ordinary-course operating and capital needs for the foreseeable future, while noting adverse conditions or unusual spending could require financing.
- Principal disclosed risks include retaining associates, reliance on network marketing, execution and regulatory requirements in new markets, foreign-exchange movements, raw-material availability and cost, competition, product liability, and compliance with debt covenants. The filing does not describe a specific material litigation contingency in the supplied text.
The filing also notes a revision to previously reported first-half 2011 comprehensive income related to currency translation on acquired BabyCare intangible assets. The revision increased reported comprehensive income and equity, but did not affect operating earnings, net earnings, or EPS.
Important facts for investors to verify
- Whether associate growth and the Lifetime Matching Bonus support sustained demand after the short-term promotion, and whether preferred-customer declines persist.
- How much reported sales growth reflects underlying volume versus price increases, pre-price-change buying, new markets, and currency movements.
- Whether new markets can develop as planned despite management’s slower-than-expected growth assessment and initial launch costs.
- The sustainability of margins and the favorable tax adjustment, including the effects of raw-material costs and foreign exchange.
- Cash generation, share-repurchase pace, the $0.6 million short-term borrowing, and continued compliance with credit-facility covenants.